Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors

Randomized, double-blind, phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor receptor-1 (IGF-1R), for advanced-stage non-small cell lung cancer (NSCLC).

(2017) S. S. Ramalingam et al.   JOURNAL OF CLINICAL ONCOLOGY

Investigation of predictive biomarkers for R1507, an anti-IGF1R antibody, in patients with advanced non-small cell lung cancer with progression after first-line chemotherapy.

(2017) K. Habben et al.   JOURNAL OF CLINICAL ONCOLOGY

Depletion of the type 1 IGF receptor delays repair of radiation-induced DNA double strand breaks

(2012) Benjamin W. Turney et al.   RADIOTHERAPY AND ONCOLOGY

Targeting IGF-1R: throwing out the baby with the bathwater?

(2011) B Basu et al.   BRITISH JOURNAL OF CANCER

A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab (MK-0646), an Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody, in Patients with Advanced Solid Tumors

(2011) F. Atzori et al.   CLINICAL CANCER RESEARCH

R1507, a Monoclonal Antibody to the Insulin-Like Growth Factor 1 Receptor, in Patients With Recurrent or Refractory Ewing Sarcoma Family of Tumors: Results of a Phase II Sarcoma Alliance for Research Through Collaboration Study

(2011) Alberto S. Pappo et al.   JOURNAL OF CLINICAL ONCOLOGY

Preliminary Efficacy of the Anti-Insulin–Like Growth Factor Type 1 Receptor Antibody Figitumumab in Patients With Refractory Ewing Sarcoma

(2011) Heribert Juergens et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I study of the anti insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma

(2011) P Moreau et al.   LEUKEMIA

Radiological response in an incidental meningioma in a patient treated with chemotherapy combined with CP-751,871, an IGF-1R inhibitor

(2010) Ian M Collins et al.   ACTA ONCOLOGICA

The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study

(2010) L R Molife et al.   BRITISH JOURNAL OF CANCER

Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer

(2010) Takuji Okusaka et al.   CANCER SCIENCE

The Insulin-like Growth Factor I Receptor/Insulin Receptor Tyrosine Kinase Inhibitor PQIP Exhibits Enhanced Antitumor Effects in Combination with Chemotherapy Against Colorectal Cancer Models

(2010) S. A. Flanigan et al.   CLINICAL CANCER RESEARCH

A Phase I Study of Weekly R1507, A Human Monoclonal Antibody Insulin-like Growth Factor-I Receptor Antagonist, in Patients with Advanced Solid Tumors

(2010) R. Kurzrock et al.   CLINICAL CANCER RESEARCH

Targeting the insulin-like growth factor I receptor inhibits proliferation and VEGF production of non-small cell lung cancer cells and enhances paclitaxel-mediated anti-tumor effect

(2010) Maria Spiliotaki et al.   LUNG CANCER

Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the ‘Arbeitsgemeinschaft Internistische Onkologie’

(2009) Stefan Boeck et al.   ANTI-CANCER DRUGS

A humanised anti-IGF-1R monoclonal antibody (AVE1642) enhances Bortezomib-induced apoptosis in myeloma cells lacking CD45

(2009) G Descamps et al.   BRITISH JOURNAL OF CANCER

Insulin Receptor Isoforms and Insulin Receptor/Insulin-Like Growth Factor Receptor Hybrids in Physiology and Disease

(2009) Antonino Belfiore et al.   ENDOCRINE REVIEWS

Phase II Study of the Anti–Insulin-Like Growth Factor Type 1 Receptor Antibody CP-751,871 in Combination With Paclitaxel and Carboplatin in Previously Untreated, Locally Advanced, or Metastatic Non–Small-Cell Lung Cancer

(2009) Daniel D. Karp et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I, Pharmacokinetic, and Pharmacodynamic Study of AMG 479, a Fully Human Monoclonal Antibody to Insulin-Like Growth Factor Receptor 1

(2009) Anthony W. Tolcher et al.   JOURNAL OF CLINICAL ONCOLOGY

The type I insulin-like growth factor receptor regulates cancer metastasis independently of primary tumor growth by promoting invasion and survival

(2009) D Sachdev et al.   ONCOGENE

Gemcitabine at fixed dose-rate in patients with advanced soft tissue sarcomas: a mono-institutional phase II study

(2008) Virginia Ferraresi et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

The Type 1 Insulin-Like Growth Factor Receptor Pathway

(2008) M. M. Chitnis et al.   CLINICAL CANCER RESEARCH

Phase I, Pharmacokinetic and Pharmacodynamic Study of the Anti–Insulinlike Growth Factor Type 1 Receptor Monoclonal Antibody CP-751,871 in Patients With Multiple Myeloma

(2008) Martha Q. Lacy et al.   JOURNAL OF CLINICAL ONCOLOGY